Morbidly obese patients remain an unsolved clinical problem,” explained co-author Gwo-Chin Lee, M.D., a hip and knee replacement surgeon at HSS. “Traditional weight loss measures have had mixed ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

This mechanism promotes feelings of fullness and supports ... that the polymer coating formed as expected and was safely eliminated within a day. GLP-1 receptor agonists have challenges including high ...

The study supports prior research that found the same thing.

Compounded semaglutide helps manage blood sugar and curb appetite for better diabetes control and weight loss. Learn how it ...

Preoperative GLP-1RA use was not significantly associated with an increased risk for postoperative aspiration pneumonia or acute respiratory failure.

By Dr. Liji Thomas, MD New research highlights how GLP-1 receptor agonists influence gut bacteria, offering insights into ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic ...